MGMT and glioblastoma: Interestingly, the calculated MGMT promotor methylation cut-off point predicting longer progression-free survival was higher (≥ 18/25 CpG sites, ≥ 72%) in comparison to the cut-off point predicting improved overall survival (≥ 11/25 CpG sites, ≥ 44%) in histopathological GBM patients.